Newman, S. G.; Aureggi, V.; Bryan, C. S.; Lautens, M. Chem. Commun. 2009, 5236.
[2]
Barrero, A. F.; Alvarez-Manzaneda, E. J.; Chahboun, R.; Meneses, R. Synlett 1999, 10, 1663. For additional studies directed toward the total synthesis of liphagal, see: (a) Deore, V.; Lohar, M. K.; Mundada, R.; Roychowdhury, A.; Vishwakarma, R.; Kumar, S. Synth. Commun. 2011, 41, 177; (b) Zhang, Y.; Oblak, E. Z.; Bolstad, E. S. D.; Anderson, A. C.; Jasinski, J. P.; Butcher, R. J.; Wright, D. L. Tetrahedron Lett. 2010, 51, 6120; (c) Mehta, G.; Likhite, N. S.; Kumar, C. S. A. Tetrahedron Lett. 2009, 50, 5260.
[3]
Marion, F.; Williams, D. E.; Patrick, B. O.; Hollander, I.; Mallon, R.; Kim, S. C.; Roll, D. M.; Feldberg, L.; van Soest, R.; Andersen, R. J. Org. Lett. 2006, 8, 321.
[4]
Sundstrom, T. J.; Anderson, A. C.; Wright, D. L. Org. Biomol. Chem. 2009, 7, 840.
[5]
For recent reviews on the therapeutic potential of phosphoinositide-3-kinase inhibitors, see: (a) Ward, S. G.; Sotsios, Y.; Dowden, J.; Bruce, I.; Finan, P. Chem. Biol. 2003, 10, 207; (b) Ward, S. G.; Finan, P. Curr. Opin. Pharmacol. 2003, 3, 426.
[6]
(a) Andersen, R.; Hollander, I.; Roll, D. M.; Kim, S. C.; Mallon, R. G.; Williams, D. E.; Marion, F. WO2006081659, 2006 [Chem. Abstr. 2006, 145, 230773]; (b) Pereira, A. R.; Strangman, W. K.; Marion, F.; Feldberg, L.; Roll, D.; Mallon, R.; Hollander, I.; Andersen, R. J. J. Med. Chem. 2010, 53, 8523.
[7]
(a) George, J. H.; Baldwin, J. E.; Adlington, R. M. Org. Lett. 2010, 12, 2394; (b) Alvarez-Manzaneda, E.; Chahboun, R.; Alvarez, E.; Cano, M. J.; Haidour, A.; Alvarez-Manzaneda, R. Org. Lett. 2010, 12, 4450; (c) Day, J. J.; McFadden, R. M.; Virgil, S. C.; Kolding, H.; Alleva, J. L.; Stoltz, B. M. Angew. Chem., Int. Ed. 2011, 50, 6814.
[8]
For a recent synthetic study of 5-epi-liphagal, see: Zhang, J.; Li, L.; Wang, Y.; Wang, W.; Xue, J.; Li, Y. Org. Lett. 2012, 14, 4528.
